person
Celeste L.
- Country
- France
- Department
- Centre d’Investigation Clinique (CIC)
Research Overview
assignment
50
Clinical Trials ·
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Phase 1/2a Study of REGN10597 Alone or with Cemiplimab in Patients with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal Cell Carcinoma
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
location_city
5
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
223
Sites with multiple studies
Has run more than one trial at 223 of 408 partner sites.
Specializations
Melanoma Research
Specializes in advanced therapeutic approaches for metastatic melanoma and stage III melanoma, with particular focus on immunotherapy treatments and targeted therapies.
- Advanced and Metastatic Disease Management
- BRAF-Mutated Melanoma Treatment
- Neoadjuvant Therapy Approaches
Skin Cancer Therapeutics
Conducts research in treating cutaneous squamous cell carcinoma and other advanced skin cancers, exploring novel therapeutic combinations and treatment strategies.
- Immunotherapy Applications
- Combination Treatment Approaches
- Advanced Disease Management
Innovative Treatment Approaches
Investigates novel therapeutic combinations including checkpoint inhibitors and experimental agents for treating resistant or refractory cancers.
- Drug Resistance Management
- Novel Therapeutic Combinations
- Advanced Solid Tumor Treatment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.